Pain intensity (measure on a 0‐3 four‐point scale) · UC patients
1 finding from 1 review
Pain frequency or change in pain frequency · UC patients
1 finding from 1 review
Withdrawals due to adverse events · UC patients
1 finding from 1 review
Treatment success as defined by the authors · UC patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pain frequency or change in pain frequency · UC patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pain intensity (measure on a 0‐3 four‐point scale) · UC patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · UC patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pain intensity (0‐10cm visual analogue scale) · UC patients
1 finding from 1 review
Withdrawals due to adverse events · UC patients
It is very uncertain whether low FODMAPs diet changes withdrawal due to adverse events compared with sham diet (very low certainty).
1 finding from 1 review
Treatment success as defined by the authors · UC patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pain frequency or change in pain frequency · UC patients
2 findings from 1 review
Pain intensity (end of intervention, unidentified 0‐10 scale) · UC patients
1 finding from 1 review
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · UC patients
1 finding from 1 review
Failure to maintain clinical or endoscopic remission · Patients with quiescent ulcerative colitis
Oral 5‐aminosalicylic acid leads to lower failure to maintain clinical or endoscopic remission compared with placebo (high certainty).
1 finding from 1 review
Failure to maintain clinical or endoscopic remission · Patients with quiescent ulcerative colitis
Once‐daily dosing showed no clear difference in failure to maintain clinical or endoscopic remission compared with conventional dosing (high certainty).
1 finding from 1 review
Failure to adhere to medication regimen · Patients with quiescent ulcerative colitis
Once‐daily dosing showed no clear difference in failure to adhere to study medication regimen compared with conventional dosing (moderate certainty).
1 finding from 1 review
Adverse event · Patients with quiescent ulcerative colitis
Once‐daily dosing showed no clear difference in adverse event compared with conventional dosing (high certainty).
1 finding from 1 review
Serious adverse events · Patients with quiescent ulcerative colitis
Once‐daily dosing showed no clear difference in serious adverse events compared with conventional dosing (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with quiescent ulcerative colitis
It is very uncertain whether once‐daily dosing changes withdrawal due to adverse events compared with conventional dosing (very low certainty).
1 finding from 1 review
Exclusion/withdrawal after entry · Patients with quiescent ulcerative colitis
Once‐daily dosing showed no clear difference in exclusion/withdrawal after entry compared with conventional dosing (high certainty).
1 finding from 1 review